Proteostasis Therapeutics Inc (NASDAQ:PTI) major shareholder Enterprise Associates 12 New bought 2,000,000 shares of the stock in a transaction dated Monday, December 18th. The shares were acquired at an average price of $5.00 per share, with a total value of $10,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Proteostasis Therapeutics Inc (NASDAQ:PTI) opened at $5.02 on Wednesday. Proteostasis Therapeutics Inc has a 52 week low of $1.41 and a 52 week high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. The business had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. equities research analysts predict that Proteostasis Therapeutics Inc will post -2.47 EPS for the current fiscal year.

PTI has been the subject of several recent analyst reports. Robert W. Baird raised their target price on Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Leerink Swann raised their target price on Proteostasis Therapeutics from $6.00 to $8.00 in a research note on Tuesday, December 12th. Zacks Investment Research downgraded Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Proteostasis Therapeutics in a research note on Tuesday.

A number of large investors have recently bought and sold shares of PTI. JPMorgan Chase & Co. grew its stake in Proteostasis Therapeutics by 425.4% in the third quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock worth $2,361,000 after purchasing an additional 910,550 shares in the last quarter. Bain Capital Public Equity Management LLC acquired a new position in Proteostasis Therapeutics in the second quarter worth about $1,233,000. Jennison Associates LLC grew its stake in Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after purchasing an additional 120,575 shares in the last quarter. FMR LLC grew its stake in Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after purchasing an additional 66,111 shares in the last quarter. Finally, Sabby Management LLC grew its stake in Proteostasis Therapeutics by 109.6% in the second quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after purchasing an additional 65,451 shares in the last quarter. Institutional investors and hedge funds own 68.03% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Proteostasis Therapeutics Inc (PTI) Major Shareholder Enterprise Associates 12 New Buys 2,000,000 Shares of Stock” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/proteostasis-therapeutics-inc-pti-major-shareholder-enterprise-associates-12-new-buys-2000000-shares-of-stock/1774441.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.